BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

| NAME Graham, W Vallen | POSITION TITLE Postdoctoral Associate |
|--|---------------------------------------|
| eRA COMMONS USER NAME (credential, e.g., agency login) vgraham | |

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)

| INSTITUTION AND LOCATION | DEGREE (if applicable) | MM/YY | FIELD OF STUDY |
|--|---------------------------|---------|--------------------------|
| University of Illinois, Urbana, IL | B.S. | 6/01 | Animal Sciences |
| University of Illinois, Urbana, IL | M.S. | 6/03 | Animal Sciences |
| University of Chicago, Chicago, IL | Ph.D. | 6/10 | Mol. Path. and Mol. Med. |
| The Rockefeller University, New York, NY | Postdoc. | Present | Mol. Biol. and Biochem. |

A. Personal Statement

The overall goal of my research is to understand the molecular underpinnings of human disease and exploit unique factors for therapeutic development. In pursuit of these goals, I have trained in laboratories that have sought to understand molecular pathophysiology. During my masters, I worked on redox-driven intestinal cell differentiation and developed a bioinformatics tool for proteomic comparison. This work was in line with the lab's goals of understanding the effects of microbiota on mucus production during intestinal disease. During my PhD, I studied the molecular implication of a specific isoform of a kinase involved in epithelial barrier function. Once I found that this protein isoform was specific for the molecular events in regulating the intestinal barrier, I exploited the extra protein domain in this kinase and developed small molecule drugs that prevent protein-protein interaction at the subcellular site of action. These drugs prevented disease in our tissue culture models and in animal models of intestinal barrier leakiness and disease. During my postdoc, I have carried my training into a new avenue of molecular medicine and am studying the unique phenomenon of an amyloid capping protein. I hope to discover the molecular mechanisms of this phenomenon and develop therapeutic strategies that can be used in *in vitro* and *in vivo* models of amyloid diseases.

B. Positions and Honors

Positions and Employment

| 1999-2001 | Undergraduate Research Assistant, Department Animal Sciences, University of Illinois |
|------------|---|
| 2000 | Research Intern, Laboratoire de Biologie, Université Blaise Pascal |
| 2001- 2003 | Graduate Research Assistant, Department Animal Sciences, University of Illinois |
| 2003-2004 | Research Technologist, Department of Pathology, University of Chicago |
| 2004-2010 | Predoctoral Research Assistant, Department of Pathology, University of Chicago |
| 2011- | Postdoctoral Research Fellow, Laboratory of Molecular Biology and Biochemistry, Rockefeller |
| | University New York NY |

Other Experience and Professional Memberships (selected)

Laboratory Investigation, *ad hoc* reviewer, 2007. American Gastroenterological Association, member. American Physiological Society, member. American Association for the Advancement of Science, member.

Honors

Colgate-Palmolive Undergraduate Research Award (2000); Graduate College Travel Grant (2003); Gamma Sigma Delta Academic Honor Society (2003); FASEB Travel Award (2007); Doolittle-Harrison Fellowship (2007); Takeda Pharmaceutical Research Award (2007); Robert Priest Merit Award (2007); Biological Sciences Division Competitive Travel Award (2008); Platform Presentation Honorarium at Experimental Biology (2008); Carolyn tum Suden/Francis A. Hellebrandt Professional Opportunity Award (2008); Digestive Diseases Week poster of distinction (2009)

C. Peer-reviewed Publications

- 1. Deplancke, B., Finster, K., Graham, W. V., Collier, C. T., Thurmond, J. E., and Gaskins, H. R. Effects of Sulfate-supplemented Drinking Water on Intestinal Sulfate and Hydrogen Sulfide Concentrations and the Microbiota of the Mouse Gastrointestinal Tract. *Experimental Biology and Medicine* 228(4):424-33 (2003). PMID: 12671187
- 2. Conour, J. E., Graham, W. V., Gaskins, H. R. A combined in vitro/bioinformatic investigation of redox regulatory mechanisms governing cell cycle progression. *Physiol Genomics*. 18(2):196-205 (2004). PMID: 15138307
- 3. Graham, W. V., Tcheng, D. K., Shirk, A. L., Attene Ramos, M., Welge, M. E., and Gaskins, H. R. PhyloMAT: an automated protein motif analysis tool for phylogenomics. *J Proteome Res.* 3(6):1289-91 (2004). PMID: 15595740
- Wang, F., Graham, W. V., Wang, Y., Turner, J. R. IFN_γ and TNFα synergize to induce intestinal epithelial barrier dysfunction by upregulating MLC kinase expression *Am J Pathol*. 166(2):409-19 (2005). PMID: 15681825
- 5. Russo, J. M., Florian, P., Shen, L., Graham, W. V., Tretiakova, M. S., Gitter, A. H., Mrsny, R. J., and Turner, J. R. Distinct temporal-spatial roles for rho kinase and myosin light chain kinase in epithelial pursestring wound closure. *Gastroenterology*. 128(4):987-1001 (2005). PMID: 15825080
- Owens, S. E., Graham, W. V., Siccardi, D., Turner, J. R., Mrsny, R. J. A strategy to identify stable membrane-permeant peptide inhibitors of myosin light chain kinase. *Pharm Res.* 22(5):703-9 (2005). PMID: 15906163
- 7. Graham, W.V. The role of β 2 integrin subsets in intestinal disease: a sticky problem *Laboratory Investigation*. 86, 323–325 (2006).
- 8. Reschly, E. J., Spaulding, C., Vilimas, T., Graham, W. V., Brumbaugh, R. L., Aifantis, I., Pear, W. S., Kee, B. L. Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms. *Blood*. 107(10):4115-21 (2006). PMID: 16449526
- 9. Hu, Z., Wang, Y., Graham, W. V., Su, L., Musch, M. W., Turner, J. R. MAPKAPK-2 is a critical signaling intermediate in NHE3 activation following Na+-glucose cotransport. *J Biol Chem.* 281(34):24247-53 (2006). PMID: 16793766
- Graham, W. V., Wang, F., Clayburgh, D. R., Cheng, J. X., Yoon, B., Wang, Y., Lin, A., Turner, J. R. Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiationdependent signaling events. Characterization of the human long myosin light chain kinase promoter. *J Biol Chem.* 281(36):26205-15 (2006). PMID: 16835238
- 11. Wang, F., Schwarz, B. T., Graham, W. V., Wang, Y., Su, L., Clayburgh, D. R., Abraham, C., Turner, J. R. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. *Gastroenterology*. 131(4):1153-63 (2006). PMID: 17030185
- 12. Graham, W. V. Too much TNF? Drink your milk or FLIP out! Laboratory Investigation. 87, 518-519 (2007).
- 13. Graham, W. V., Marchiando, A. M., Shen, L., Turner, J. R. No static at all: A new perspective on molecular architecture of the tight junction. *New York Academy of Sciences* 1165:314-322 (2009). PMID: 19538322
- 14. Marchiando, A. M., Graham, W. V., Turner, J. R. Epithelial Barriers in Homeostasis and Disease. *Annual Review of Pathology* 5:119-144 (2010). PMID: 20078218
- 15. Marchiando, A. M., Shen, L., Graham, W. V., Weber, C. R., Schwarz, B. T., Austin, J. R., Raleigh, D. R., Guan, Y., Watson, A. J. M., Montrose, M. H., and Turner, J. R. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, *Journal Cell Biology* 189:111-126 (2010). PMID: 20351069
- 16. Marchiando, A. M., Shen, L., Graham, W. V., Edelblum, K. L., Duckworth, C. A., Guan, Y., Montrose, M. H., Turner, J. R., Watson, A. J. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology. 140(4):1208-1218 (2011). PMID: 21237166
- 17. Graham, W. V., Magis, A. T., Bailey, K. M., Turner, J. R., Ostrov, D. A. Crystallization and preliminary X-ray analysis of the human long myosin light chain kinase 1-specific domain IgCAM3. Acta Crystallogr Sect F Struct Biol Cryst Commun. 67:221-3 (2011). PMID: 21301090